Evolus (EOLS) Depreciation & Amortization (CF) (2017 - 2026)
Evolus (EOLS) reported Depreciation & Amortization (CF) of $2.3 million for Q1 2026, up 50.1% on a YoY basis from $1.6 million in Q1 2025, and up 4.08% quarter-over-quarter from $2.3 million in Q4 2025.
Evolus (EOLS) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends
Evolus has reported Depreciation & Amortization (CF) for 10 years, with the latest figure at $2.3 million in Q1 2026.
- For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 50.1% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $8.3 million (up 52.06% YoY), and the FY2025 full-year result was $7.5 million, up 41.7% from the prior year.
- Depreciation & Amortization (CF) for Q1 2026 stood at $2.3 million, up from $2.3 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $2.3 million in Q1 2026, with the low at $853000.0 in Q2 2022.
- Historically, Depreciation & Amortization (CF) has averaged $1.4 million across 5 years, with a median of $1.4 million in 2023.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) tumbled 54.65% — and 2025, when it jumped 79.48%.
- Evolus' Depreciation & Amortization (CF) stood at $1.0 million in 2022, then jumped by 33.69% to $1.4 million in 2023, then increased by 0.07% to $1.4 million in 2024, then soared by 64.05% to $2.3 million in 2025, then advanced by 4.08% to $2.3 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $2.3 million (Q1 2026), $2.3 million (Q4 2025), and $2.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 239.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 119.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 22.60 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 7.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 172.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 19.43 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 21.95 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 22.68 Mn |
| 10 | Evolus | 437.40 Mn | 387.61 Mn | 48.90 Mn | 2.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.35 Mn |
| Mar 31, 2026 | 2.35 Mn |
| Dec 31, 2025 | 2.25 Mn |
| Dec 31, 2025 | 2.25 Mn |
| Sep 30, 2025 | 1.95 Mn |
| Sep 30, 2025 | 1.95 Mn |
| Jun 30, 2025 | 1.74 Mn |
| Jun 30, 2025 | 1.74 Mn |
| Mar 31, 2025 | 1.56 Mn |
| Mar 31, 2025 | 1.56 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Dec 31, 2024 | 1.37 Mn |
| Sep 30, 2024 | 1.09 Mn |
| Sep 30, 2024 | 1.09 Mn |
| Jun 30, 2024 | 1.43 Mn |
| Jun 30, 2024 | 1.43 Mn |
| Mar 31, 2024 | 1.41 Mn |
| Mar 31, 2024 | 1.41 Mn |
| Dec 31, 2023 | 1.37 Mn |
| Dec 31, 2023 | 1.37 Mn |